ESC Congress 2021: Updates in Chronic Kidney Disease, Heart Failure, and Type 2 Diabetes

An overview of the FIGARO-DKD trial, which evaluated cardiovascular and renal outcomes in patients with type 2 diabetes and CKD treated with finerenone.

Rajiv Agarwal, MD, MS, shares expert insight on the results of FIGARO-DKD with respect to the trial’s primary and secondary end points.

An overview of the FIDELITY analysis, which pooled data from the FIGARO-DKD and FIDELIO-DKD trials in patients with type 2 diabetes and CKD.

A review of results from the FIDELITY pooled analysis analyzing finerenone’s impact on cardiorenal morbidity and mortality in patients with type 2 diabetes and CKD.

Rajiv Agarwal, MD, MS, considers the practical implications of the FIDELITY pooled analysis and how it may impact clinical practice.

Considerations for the benefit shown in combining finerenone with SGLT2 inhibitors in patients with type 2 diabetes and CKD.

An overview of and results from the EMPEROR-Preserved trial, which tested the effects of empagliflozin in patients with HFpEF.

Rajiv Agarwal, MD, MS, reflects on pooled data from the EMPEROR-Reduced and EMPEROR-Preserved trials.

Insight on the unmet needs in management of heart failure, specifically regarding access to therapeutic agents that can alter the course of disease.

A brief overview of the STEP trial and results from intensive blood-pressure control in elderly patients with hypertension.